Click here to get the full newsletter in your inbox, including answers to reader questions and a summary of new scientific ...

FDA approval for Zepbound in treating sleep apnea was based on two previous Eli Lilly-sponsored trials published in the New England Journal of Medicine involving nearly 470 participants ...

Although the new FDA green light doesn't expand the number of people who may be eligible for the drug, since the sleep apnea approval is specifically for people with obesity, it could lead to ...

Veozah, which entered the market in 2023, is known for reducing hot flashes without the use of hormones. However, recent studies have raised concerns about its safety. The FDA has found that Veozah ...

SSRIs and selective norepinephrine reuptake inhibitors (SNRIs) have been extensively studied for the management of hot flashes with varying results. [1] In this well-done trial, escitalopram at ...

Low-dose paroxetine (Brisdelle) is the only non-hormone treatment approved by the Food & Drug Administration for ... may improve menstrual irregularity and vasomotor symptoms (which include hot ...

For that reason, the FDA said, it's impossible ... the company said. Veozah was approved in 2023. It works without hormones to reduce hot flashes by blocking a receptor called neurokinin B ...

It works without hormones to reduce hot flashes by blocking a receptor called neurokinin B, which plays a role in the brain's regulation of body temperature.Since its approval, use of the medication ...